Home Other Building Blocks 839712-12-8
839712-12-8,MFCD19443701
Catalog No.:AA00G3L7

839712-12-8 | Cariprazine

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥95%
in stock  
$46.00   $32.00
- +
5mg
≥95%
in stock  
$199.00   $139.00
- +
10mg
≥95%
in stock  
$348.00   $243.00
- +
100mg
97%
in stock  
$594.00   $416.00
- +
250mg
97%
in stock  
$809.00   $567.00
- +
1g
97%
in stock  
$1,640.00   $1,148.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00G3L7
Chemical Name:
Cariprazine
CAS Number:
839712-12-8
Molecular Formula:
C21H32Cl2N4O
Molecular Weight:
427.4110
MDL Number:
MFCD19443701
SMILES:
O=C(N(C)C)N[C@@H]1CC[C@H](CC1)CCN1CCN(CC1)c1cccc(c1Cl)Cl
Properties
Computed Properties
 
Complexity:
491  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
5  
XLogP3:
4.3  

Literature

Title: Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis.

Journal: Toxicology and applied pharmacology 20180615

Title: Cariprazine: First Global Approval.

Journal: Drugs 20151101

Title: Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.

Journal: Expert opinion on drug metabolism & toxicology 20130201

Title: Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.

Journal: Bioorganic & medicinal chemistry letters 20120515

Title: Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.

Journal: Psychopharmacology 20111201

Title: Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.

Journal: Neurochemistry international 20111101

Title: In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.

Journal: European journal of pharmacology 20111015

Title: Pharmacokinetics and metabolism update for some recent antipsychotics.

Journal: Expert opinion on drug metabolism & toxicology 20110701

Title: [The dopamin D3 receptor--the gray eminence of pharmacotherapy?].

Journal: Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20100901

Title: Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.

Journal: Current opinion in investigational drugs (London, England : 2000) 20100701

Title: Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.

Journal: The Journal of pharmacology and experimental therapeutics 20100401

Title: Seneca N, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011 Dec;218(3):579-8

Title: Kiss B, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010 Apr;333(1):328-40.

Title: Zimnisky R, et al. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013 Mar;226(1):91-100

Title: Gao Y, et al. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect. 2015 Feb;3(1):e00073.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:839712-12-8 Molecular Formula|839712-12-8 MDL|839712-12-8 SMILES|839712-12-8 Cariprazine